Compare Genuine Parts Company (GPC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Genuine Parts Company trades at $131.49 (market cap $18.02B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Genuine Parts Company is far larger — about 18.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Genuine Parts Company pays a 3.25% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GPC | MRVI | |
|---|---|---|
Market Cap | $18.02B | $972.90M |
Volume | 744,000 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $9.00 |
52-Week Low | $92.47 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.11B | $1.08B |
Dividend Yield | 3.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $131.63, up 1.55% today, with a bullish technical signal and analyst consensus price target of $145.75. Recent earnings show mixed results, with Q1 and Q2 2026 beats but a Q4 2025 miss, while net income margin remains thin at 0.13%. The company is progressing with its planned separation into automotive and industrial businesses by Q1 2027, a key strategic move highlighted in recent news.
The outlook is cautiously optimistic, supported by the corporate split catalyst and steady revenue growth, but risks include low profitability margins and rising debt levels. Analyst sentiment leans positive with 10 buy ratings, though valuation metrics like a high P/E of 522.84 warrant attention for potential investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
